Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Panleukopenia Virus, Str

Verify with FDA CVM →

66 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
66
Total Reports
12
Deaths Reported
1820.0%
Death Rate

Active Ingredients

Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Panleukopenia Virus, Str

Administration Routes

SubcutaneousUnknown

Species Affected

Cat 66

Most Affected Breeds

Domestic Shorthair 45
Domestic Longhair 5
American Curl Shorthair 3
Domestic Mediumhair 2
Maine Coon 2
Bengal 2
Siamese 2
Russian 1
Persian 1
Cat (unknown) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 29
Not eating 15
Vomiting 14
Emesis (multiple) 13
Diarrhoea 12
Fever 10
Anaphylaxis 10
Lack of efficacy - NOS 9
Open mouth breathing 7
Panting 6
Death by euthanasia 6
Death 6

Outcome Breakdown

Ongoing
34 (51.5%)
Recovered/Normal
16 (24.2%)
Euthanized
6 (9.1%)
Died
6 (9.1%)
Outcome Unknown
3 (4.5%)
Recovered with Sequela
1 (1.5%)

Data Summary

Metric Value
Total adverse event reports 66
Reports involving death 12
Case-fatality rate (reported events) 1820.0%
Distinct species in reports 1
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Panleukopenia Virus, Str Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 66 adverse event reports referencing Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Panleukopenia Virus, Str, including 12 reports in which the animal died — a 1820.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Panleukopenia Virus, Str. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Panleukopenia Virus, Str reports are Cat (66 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (45), Domestic Longhair (5), American Curl Shorthair (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Panleukopenia Virus, Str are Lethargy (see also Central nervous system depression in Neurological) (29), Not eating (15), Vomiting (14), Emesis (multiple) (13). Of the 66 reports with a coded outcome, Ongoing is the leading category at 51.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Panleukopenia Virus, Str.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial